Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25-35) in rat PC12 cells

NeuroReport

Volumn 9, Issue 7, 1998, Pages 1519-1522

  Svensson, Anne Lie ^a   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Donepezil; Neuroprotection; Nicotinic receptors; PC12 cells; Tacrine; Amyloid(25 35)

Indexed keywords

AMYLOID BETA PROTEIN; DONEPEZIL; MECAMYLAMINE; NICOTINIC RECEPTOR; TACRINE; TUBOCURARINE CHLORIDE;

ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; DRUG ANTAGONISM; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL;

EID: 0032507596     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199805110-00050     Document Type: Article

References (35)

1. Selkoe DJ. Annu Rev Cell Biol 10, 373-403 (1994).
2. Yankner BA, Duffy LK and Kirschner DA. Science 250, 279-282 (1990).
3. Mattson MP, Cheng B, Davis D et al. J Neurosci 12, 376-389 (1992).
4. Behl C, Davis JB, Lesley R and Schubert D. Cell 77, 817-827 (1994).
5. Kowall NW, Beal MF, Busciglio J et al. Proc Natl Acad Sci USA 88, 7247-7251 (1991).
6. Pike CJ, Burdick D, Walencewicz AJ et al. J Neurosci 13, 1676-1687 (1993).
7. Ahe K and Kimura H. J Neurochem 67, 2074-2078 (1996).
8. Copani A, Bruno V and Battaglia G. Mol Pharmacol 47, 890-897 (1995).
9. Gillardon F, Skutella T and Uhlmann E. Brain Res 706, 169-172 (1996).
10. Nordberg A. Cerebrovasc Brain Metab Rev 4, 303-328 (1992).
11. Bierer LM, Haroutunian V, Gabriel S et al. J Neurochem 64, 749-760 (1995).
12. Knapp MJ, Knopman DS, Solomon PR et al. JAMA 271, 985-991 (1994).
13. Rogers SL, Friedhoff LT and the Donepezil Study Group. Dementia 7, 293-303 (1996).
14. Nitsch RM, Slack BE, Wurtman RJ and Growdon JH. Science 258, 304-307 (1992).
15. Pittel Z, Heldman E, Barg J et al. Brain Res 742, 299-304 (1996).
16. Zamani MR, Allen YS, Owen GP and Gray JA. NeuroReport 8, 513-517 (1997).
17. Kihara T, Shimohama S, Sawada H et al. Ann Neurol 42, 159-163 (1997).
18. Akaike A, Tamura Y, Yokota T et al. Brain Res 644, 181-187 (1994).
19. Donnelly-Roberts DL, Xue IC, Arneric SP and Sullivan JP. Brain Res 719, 36-44 (1996).
20. Svensson A-L and Nordberg A. NeuroReport 7, 2201-2205 (1996).
21. Rogers SW, Mandelzys A, Deneris ES et al. J Neurosci 12, 4611-4623 (1992).
22. Henderson LP, Gdovin MJ, Liu CL et al. J Neurosci 14, 1153-1163 (1994).
23. Shearman MS, Ragan CI and Iversen LL. Proc Natl Acad Sci USA 91, 1470-1474 (1994).
24. Greene LA and Tischler A. Proc Natl Acad Sci USA 73, 2424-2428 (1976).
25. Hansen MB Nielsen SE and Berg K. J Immunol Methods 119, 203-210 (1989).
26. Hertel C, Hauser R, Schubenel R et al. J Neurochem 67, 272-276 (1996).
27. Yan SD, Chen X, Fu J et al. Nature 382, 685-691 (1996).
28. Lahiri DK, Lewis S and Farlow MR. J Neurosci Res 37, 777-787 (1994).
29. Mori F, Lai C-C, Fusi F and Giacobini E. NeuroReport 6, 633-636 (1995).
30. Davenport CJ. Monyer H and Choi DW. Eur J Pharmacol 154, 73-78 (1988).
31. Ved HS, Koenig ML, Dave JR and Doctor BP. NeuroReport 8, 963-968 (1997).
32. McGehee DS and Role LW. Annu Rev Physiol 57, 521-546 (1995).
33. Wonnacott S. Trends Pharmacol Sci 11, 216-218 (1990).
34. Svensson A-L and Nordherg A. Interaction of tacrine, galanthamine, NXX-066 and E2020 with neuronal α4β2 nicotinic receptors expressed in fibroblast cells. In: Iqbal K, Winhlad B, Nishimura T, Takeda M and Wisniewski HM, eds. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Chichester: John Wiley & Sons Ltd, 1997: 751-756.
35. Johansson M, Hellström-Lindahl E and Nordberg A. Dementia 7, 111-117 (1996).